Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:GRAB NYSEAMERICAN:URG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50$4.44$1.34▼$5.15$628.49M0.761.25 million shs4.32 million shsGRABGrab$3.57$3.65$3.18▼$6.62$14.63B0.8950.09 million shs82.02 million shsURGUr Energy$1.50$1.67$0.97▼$2.35$596M0.8814.19 million shs47.05 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+4.17%-0.66%+21.95%+216.90%GRABGrab0.00%+8.18%+1.71%+0.28%-23.39%URGUr Energy0.00%-4.46%+2.04%+3.45%+32.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.50$4.44$1.34▼$5.15$628.49M0.761.25 million shs4.32 million shsGRABGrab$3.57$3.65$3.18▼$6.62$14.63B0.8950.09 million shs82.02 million shsURGUr Energy$1.50$1.67$0.97▼$2.35$596M0.8814.19 million shs47.05 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+4.17%-0.66%+21.95%+216.90%GRABGrab0.00%+8.18%+1.71%+0.28%-23.39%URGUr Energy0.00%-4.46%+2.04%+3.45%+32.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50155.56% UpsideGRABGrab 2.90Moderate Buy$6.1973.36% UpsideURGUr Energy 3.33Buy$2.5771.11% UpsideCurrent Analyst Ratings BreakdownLatest URG, ACRS, and GRAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/2/2026GRABGrab Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/14/2026URGUr Energy B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/12/2026URGUr Energy Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.005/12/2026URGUr Energy Northland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$2.355/6/2026GRABGrab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/6/2026GRABGrab Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.905/6/2026GRABGrab China RenaissanceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$5.005/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$8.37M75.12N/AN/A$0.85 per share5.29GRABGrab$3.37B4.34$0.11 per share32.87$1.65 per share2.16URGUr Energy$27.21M21.90N/AN/A$0.20 per share7.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)GRABGrab$268M$0.01357.3625.501.6210.67%5.79%3.28%7/30/2026 (Estimated)URGUr Energy-$74.90M-$0.13N/A75.00N/A-298.18%-98.81%-38.49%8/4/2026 (Estimated)Latest URG, ACRS, and GRAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/5/2026Q1 2026GRABGrab$0.0188-$0.01-$0.0288-$0.01$921.71 million$955.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AGRABGrabN/AN/AN/AN/AN/AURGUr EnergyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03GRABGrab0.061.671.65URGUr Energy0.834.443.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%GRABGrab55.52%URGUr Energy57.51%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%GRABGrab3.60%URGUr Energy1.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableGRABGrab12,0124.10 billion3.95 billionOptionableURGUr Energy10397.33 million390.86 millionNot OptionableURG, ACRS, and GRAB HeadlinesRecent News About These Companies3 Penny Stocks Under $5 Backed by Real Revenue Growth...2 hours ago | marketbeat.comUr-Energy Inc.: Ur-Energy Celebrates 100th Shipment of Yellowcake from Lost Creek ISR Uranium Mine, WyomingJune 17 at 2:56 PM | finanznachrichten.deUr-Energy Celebrates 100th Shipment of Yellowcake from Lost Creek ISR Uranium Mine, WyomingJune 17 at 7:00 AM | accessnewswire.comAUr-Energy Reports Results of Annual General and Special Meeting of ShareholdersJune 5, 2026 | accessnewswire.comAUr-Energy Stock Short Interest Report | AMEX:URG | BenzingaMay 28, 2026 | benzinga.comCan Energy Fuels Maintain Its Strong Uranium Growth in 2026?May 20, 2026 | zacks.comUr-Energy (URG) Reopens a Wyoming Uranium Mine That Has Been Idle Since 1992May 15, 2026 | finance.yahoo.comUr-Energy (AMEX:URG) Stock, Earnings Estimates, EPS, And RevenueMay 13, 2026 | benzinga.comUr-Energy Inc.: Ur-Energy Reminds Shareholders and Interested Parties of First Quarter Conference Call and WebcastMay 11, 2026 | finanznachrichten.deUr-Energy Reminds Shareholders and Interested Parties of First Quarter Conference Call and WebcastMay 11, 2026 | accessnewswire.comAUr Energy (URG) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2026 | zacks.comUr-Energy Reports Q1 2026 Results and Announces Conference Call and WebcastMay 8, 2026 | accessnewswire.comAUr-Energy starts uranium mining at Shirley Basin project in WyomingApril 30, 2026 | mining.comUr-Energy Commences Operations at its Shirley Basin ISR Project, Wyoming, Advancing U.S. Uranium ProductionApril 23, 2026 | accessnewswire.comAIs Ur-Energy Inc. (URG) the Fastest Growing Rare Earth Stock to Invest In?April 17, 2026 | finance.yahoo.comNoble Plains Uranium (NOBL) advances US strategy with Ur-Energy processing agreementApril 16, 2026 | msn.comNoble Plains Uranium Announces Strategic Letter of Intent with Ur-Energy for Potential Processing of Shirley Central Uranium ProductionApril 15, 2026 | newsfilecorp.comNCanaccord Genuity initiates coverage of Ur-Energy (URG) with buy recommendationApril 3, 2026 | msn.comWall Street Backs Ur-Energy as a Top Made-in-America Uranium PlayApril 2, 2026 | 247wallst.comWhy Ur-Energy’s Higher 2026 Spending Hasn’t Derailed Wall Street’s Broader ViewMarch 24, 2026 | msn.comHC Wainwright lowers its price target on Ur-Energy Inc. (URG) to $2.30 from $2.60March 24, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in FocusBy Jeffrey Neal Johnson | June 4, 2026Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for InvestorsBy Chris Markoch | June 2, 2026As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingBy Jessica Mitacek | June 4, 2026Broadcom's Whiplash: Shares Tank After Pre-Earnings SurgeBy Leo Miller | June 5, 2026URG, ACRS, and GRAB Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.50 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.31 -0.19 (-4.20%) As of 06/18/2026 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Grab NASDAQ:GRAB$3.57 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.58 +0.01 (+0.14%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. The company offers its Grab ecosystem, a single platform with superapps for driver- and merchant-partners and consumers, that allows access to mobility, delivery, digital financial services, and enterprise sector offerings. Grab Holdings Limited is headquartered in Singapore.Ur Energy NYSEAMERICAN:URG$1.50 0.00 (0.00%) Closing price 06/18/2026 04:10 PM EasternExtended Trading$1.52 +0.02 (+1.67%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. Its flagship property is the Lost Creek project comprising a total of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 35,400 acres located in the Great Divide Basin, Wyoming. The company was incorporated in 2004 and is headquartered in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
